Results · Apr-Jun 2026 · filed 7 Aug 2026
Aarti Pharmalabs Q1 FY27 results
BlockbusterBlockbuster: sales up 20% or more & profit up 30% or more on the same quarter last year, with a wider operating margin.
Sales grew 39% to ₹536 crore from ₹386 crore in Apr-Jun 2025.
Operating profit grew 43% to ₹136 crore, an operating margin of 25.4% (up 0.7 points from a year ago).
Net profit grew 54% to ₹76.1 crore from ₹49.5 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −8%, net profit +25%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 535.8 | 386.2 | +39% |
| Operating profit (EBITDA) | 136.1 | 95.2 | +43% |
| Operating margin | 25.4% | 24.7% | +0.7 pts |
| Net profit | 76.1 | 49.5 | +54% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 10 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 10 Aug 2026Announcement under Regulation 30 (LODR)-Investor Presentation
- 9 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 7 Aug 2026Announcement under Regulation 30 (LODR)-Change in Directorate
- 7 Aug 2026Approved Capacity Addition For Development Of Intermediate Block
- 7 Aug 2026Announcement under Regulation 30 (LODR)-Change in Directorate
- 7 Aug 2026Approval Of Unaudited Financial Results (Standalone And Consolidated)For The Quarter Ended June 30, 2026
- 7 Aug 2026Board Meeting Outcome for Outcome Of Board Meeting Held On August 07, 2026.
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.